Effects of cystic fibrosis medication on lung and pancreas health in young children
Pulmonary and pancreatic response to cystic fibrosis modulator therapy in young children
This study is looking at how a new medication for cystic fibrosis can help the lungs and pancreas of young kids aged 2 to 5, with the hope of preventing lung problems and improving how their pancreas works.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Emory University NIH-funded |
| Lab location | 1 site (Atlanta, United States) |
| Project ID | NIH-11088841 on NIH RePORTER |
What this research studies
This research investigates how a new medication for cystic fibrosis, known as highly effective modulator therapy (HEMT), affects the lungs and pancreas in young children aged 2 to 5 years. The study aims to understand whether this therapy can prevent lung disease progression and improve pancreatic function, which is often compromised in cystic fibrosis. By monitoring the health of these children over time, researchers hope to identify the benefits of early treatment with this medication. The approach includes assessing pulmonary function and pancreatic health through clinical evaluations and tests.
Who could benefit from this research
Good fit: Ideal candidates for this research are young children aged 2 to 5 years diagnosed with cystic fibrosis.
Not a fit: Patients older than 5 years or those without a cystic fibrosis diagnosis may not receive any benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved lung and pancreatic health in young children with cystic fibrosis, potentially reducing the severity of the disease.
How similar studies have performed: Previous research has shown promising results with similar therapies in older patients, but this specific approach in young children is relatively novel.
Where this research is happening
Atlanta, United States
- Emory University — Atlanta, United States (Active)
Researchers
- Principal investigator: Stecenko, Arlene a — Emory University
- Study coordinator: Stecenko, Arlene a
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.